Interim Report 2026
Filed with HKEX · Stock code 2563 · · 75 pages · English
Corporate Information Financial Highlights Management Discussion and Analysis Corporate Governance and Other Supplementary Information Consolidated Balance Sheets Consolidated Statement of Profit or Loss 32 Consolidated Statement of Cash Flows 34 Consolidated Statement of Changes in Owners’ Equity 36 Notes to the Interim Condensed Consolidated 38 Financial Information Definitions Glossary of Techn
Beijing Biostar Pharmaceuticals Co., Ltd. on 6ix
Earlier from Beijing Biostar Pharmaceuticals
- Breaking the "Untreatable": Biostar Pharma's UTD1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases
- The FDA Granted Orphan Drug Designation to Biostar Pharma's Utidelone for the Treatment of Pancreatic Cancer
- Biostar Pharma Successively Achieved First Patient Dosing for Two Phase II/III Multiregional Clinical Trials of Utidelone Capsule (UTD2)
Later from Beijing Biostar Pharmaceuticals
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
- Voluntary announcement - UTD2 of biostar achieves first patient dosing in phase iii clinical study for HER2-negative advanced breast cancer
Follow Beijing Biostar Pharmaceuticals into a list and get an email when it puts out news.
Follow Beijing Biostar Pharmaceuticals